KR19990077344A - 합성 il-10 동족체 - Google Patents

합성 il-10 동족체 Download PDF

Info

Publication number: KR19990077344A
Authority: KR; South Korea
Prior art keywords: peptide; substance; group; amino acid; polypeptide
Prior art date: 1996-01-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1019980705491A

Other languages

English (en)

Korean (ko)

Inventor

라르센 크리스티안 그론호지

보르발라 게쎄르

Original Assignee

라르센 스틴 그래스티드

스티노 리서치 그룹 에이/에스

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-18

Filing date

1997-01-16

Publication date

1999-10-25

1997-01-16 Application filed by 라르센 스틴 그래스티드, 스티노 리서치 그룹 에이/에스 filed Critical 라르센 스틴 그래스티드

1999-10-25 Publication of KR19990077344A publication Critical patent/KR19990077344A/ko

Status Ceased legal-status Critical Current

Links

102000003814 Interleukin-10 Human genes 0.000 title description 66
108090000174 Interleukin-10 Proteins 0.000 title description 66
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 202
239000000126 substance Substances 0.000 claims abstract description 103
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 92
150000001413 amino acids Chemical class 0.000 claims abstract description 81
229920001184 polypeptide Polymers 0.000 claims abstract description 59
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 28
206010033645 Pancreatitis Diseases 0.000 claims abstract description 25
125000000539 amino acid group Chemical group 0.000 claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
230000006433 tumor necrosis factor production Effects 0.000 claims abstract description 14
125000003277 amino group Chemical group 0.000 claims abstract description 10
GTORPNRZTBKYJB-AIEIIIEWSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]hexanoyl Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 GTORPNRZTBKYJB-AIEIIIEWSA-N 0.000 claims description 148
108010034537 alanyl-tyrosyl-methionyl-threonyl-methionyl-lysyl-isoleucyl-arginyl-asparagine Proteins 0.000 claims description 148
238000004519 manufacturing process Methods 0.000 claims description 59
238000000034 method Methods 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
201000010099 disease Diseases 0.000 claims description 25
238000011282 treatment Methods 0.000 claims description 23
239000000463 material Substances 0.000 claims description 17
230000004071 biological effect Effects 0.000 claims description 13
230000001351 cycling effect Effects 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 5
208000009608 Papillomavirus Infections Diseases 0.000 claims description 4
208000036142 Viral infection Diseases 0.000 claims description 4
230000009385 viral infection Effects 0.000 claims description 4
230000008878 coupling Effects 0.000 claims description 3
238000010168 coupling process Methods 0.000 claims description 3
238000005859 coupling reaction Methods 0.000 claims description 3
125000006239 protecting group Chemical group 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
230000010933 acylation Effects 0.000 claims description 2
238000005917 acylation reaction Methods 0.000 claims description 2
238000010647 peptide synthesis reaction Methods 0.000 claims description 2
229920005989 resin Polymers 0.000 claims description 2
239000011347 resin Substances 0.000 claims description 2
239000007790 solid phase Substances 0.000 claims description 2
230000006641 stabilisation Effects 0.000 claims description 2
238000011105 stabilization Methods 0.000 claims description 2
230000002194 synthesizing effect Effects 0.000 claims description 2
208000030507 AIDS Diseases 0.000 claims 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
230000009435 amidation Effects 0.000 claims 1
238000007112 amidation reaction Methods 0.000 claims 1
229910052698 phosphorus Inorganic materials 0.000 claims 1
239000011574 phosphorus Substances 0.000 claims 1
230000001012 protector Effects 0.000 claims 1
229940024606 amino acid Drugs 0.000 description 71
210000001744 T-lymphocyte Anatomy 0.000 description 70
229940076144 interleukin-10 Drugs 0.000 description 65
210000001616 monocyte Anatomy 0.000 description 58
210000004027 cell Anatomy 0.000 description 57
108090001007 Interleukin-8 Proteins 0.000 description 48
102000004890 Interleukin-8 Human genes 0.000 description 48
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 46
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 43
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 43
108060008682 Tumor Necrosis Factor Proteins 0.000 description 30
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 30
230000000694 effects Effects 0.000 description 30
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 28
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 27
230000004044 response Effects 0.000 description 26
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 23
102100021943 C-C motif chemokine 2 Human genes 0.000 description 21
241000283973 Oryctolagus cuniculus Species 0.000 description 21
230000005764 inhibitory process Effects 0.000 description 20
230000021995 interleukin-8 production Effects 0.000 description 20
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 20
230000006698 induction Effects 0.000 description 19
102000004127 Cytokines Human genes 0.000 description 18
108090000695 Cytokines Proteins 0.000 description 18
239000000203 mixture Substances 0.000 description 18
210000002966 serum Anatomy 0.000 description 18
102000004388 Interleukin-4 Human genes 0.000 description 17
108090000978 Interleukin-4 Proteins 0.000 description 17
206010033647 Pancreatitis acute Diseases 0.000 description 17
201000003229 acute pancreatitis Diseases 0.000 description 17
210000000265 leukocyte Anatomy 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 17
108010074328 Interferon-gamma Proteins 0.000 description 16
239000002158 endotoxin Substances 0.000 description 16
102100037850 Interferon gamma Human genes 0.000 description 15
238000002474 experimental method Methods 0.000 description 15
230000002401 inhibitory effect Effects 0.000 description 15
239000000556 agonist Substances 0.000 description 13
239000003613 bile acid Substances 0.000 description 13
102000000589 Interleukin-1 Human genes 0.000 description 12
108010002352 Interleukin-1 Proteins 0.000 description 12
101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 11
239000012980 RPMI-1640 medium Substances 0.000 description 11
241000700159 Rattus Species 0.000 description 11
KDGBLMDAPJTQIW-RHYQMDGZSA-N Thr-Met-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N)O KDGBLMDAPJTQIW-RHYQMDGZSA-N 0.000 description 11
230000035605 chemotaxis Effects 0.000 description 11
230000007935 neutral effect Effects 0.000 description 11
-1 superoxide anions Chemical class 0.000 description 11
XKXAZPSREVUCRT-BPNCWPANSA-N Ala-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 XKXAZPSREVUCRT-BPNCWPANSA-N 0.000 description 10
101710155857 C-C motif chemokine 2 Proteins 0.000 description 10
239000012981 Hank's balanced salt solution Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 9
SACHLUOUHCVIKI-GMOBBJLQSA-N Ile-Arg-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SACHLUOUHCVIKI-GMOBBJLQSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 9
239000000427 antigen Substances 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
230000001939 inductive effect Effects 0.000 description 9
238000005259 measurement Methods 0.000 description 9
230000002269 spontaneous effect Effects 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
201000002364 leukopenia Diseases 0.000 description 8
231100001022 leukopenia Toxicity 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
102000006354 HLA-DR Antigens Human genes 0.000 description 7
108010058597 HLA-DR Antigens Proteins 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
239000002253 acid Substances 0.000 description 7
206010003246 arthritis Diseases 0.000 description 7
238000003556 assay Methods 0.000 description 7
239000012634 fragment Substances 0.000 description 7
238000011534 incubation Methods 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
238000013508 migration Methods 0.000 description 7
230000005012 migration Effects 0.000 description 7
210000005087 mononuclear cell Anatomy 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
102000001189 Cyclic Peptides Human genes 0.000 description 6
108010069514 Cyclic Peptides Proteins 0.000 description 6
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
230000027455 binding Effects 0.000 description 6
230000003399 chemotactic effect Effects 0.000 description 6
239000006071 cream Substances 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
239000004033 plastic Substances 0.000 description 6
229920003023 plastic Polymers 0.000 description 6
230000004043 responsiveness Effects 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
238000001262 western blot Methods 0.000 description 6
241000283707 Capra Species 0.000 description 5
102000019034 Chemokines Human genes 0.000 description 5
108010012236 Chemokines Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000009471 action Effects 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000001605 fetal effect Effects 0.000 description 5
230000001506 immunosuppresive effect Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000017307 interleukin-4 production Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000011555 rabbit model Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
201000001320 Atherosclerosis Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 4
102000015696 Interleukins Human genes 0.000 description 4
108010063738 Interleukins Proteins 0.000 description 4
206010027476 Metastases Diseases 0.000 description 4
230000006052 T cell proliferation Effects 0.000 description 4
208000000260 Warts Diseases 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
244000309466 calf Species 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000007721 medicinal effect Effects 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
230000035939 shock Effects 0.000 description 4
201000010153 skin papilloma Diseases 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
238000008157 ELISA kit Methods 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
229930182566 Gentamicin Natural products 0.000 description 3
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
201000005569 Gout Diseases 0.000 description 3
101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
102000019223 Interleukin-1 receptor Human genes 0.000 description 3
108050006617 Interleukin-1 receptor Proteins 0.000 description 3
102000004551 Interleukin-10 Receptors Human genes 0.000 description 3
108010017550 Interleukin-10 Receptors Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
101710090398 Viral interleukin-10 homolog Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000011324 bead Substances 0.000 description 3
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
210000000172 cytosol Anatomy 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000000586 desensitisation Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
102000052620 human IL10 Human genes 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
239000002955 immunomodulating agent Substances 0.000 description 3
229940121354 immunomodulator Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000011268 leukocyte chemotaxis Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
201000005962 mycosis fungoides Diseases 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000004417 polycarbonate Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
238000011160 research Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
RNHKOQHGYMTHFR-UBHSHLNASA-N Ala-Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 RNHKOQHGYMTHFR-UBHSHLNASA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 2
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000037273 Pathologic Processes Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
108010077895 Sarcosine Proteins 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
206010053879 Sepsis syndrome Diseases 0.000 description 2
241000282887 Suidae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
230000009809 T cell chemotaxis Effects 0.000 description 2
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
AHOLTQCAVBSUDP-PPCPHDFISA-N Thr-Ile-Lys Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O AHOLTQCAVBSUDP-PPCPHDFISA-N 0.000 description 2
MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000002975 chemoattractant Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
238000013461 design Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002998 immunogenetic effect Effects 0.000 description 2
230000002584 immunomodulator Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
231100000225 lethality Toxicity 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
108010017391 lysylvaline Proteins 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
230000028550 monocyte chemotaxis Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
210000000277 pancreatic duct Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000009054 pathological process Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
201000007094 prostatitis Diseases 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000035456 regulation of T cell proliferation Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000011146 sterile filtration Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000035899 viability Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
XABCFXXGZPWJQP-BYPYZUCNSA-N (S)-3-aminoadipic acid Chemical compound OC(=O)C[C@@H](N)CCC(O)=O XABCFXXGZPWJQP-BYPYZUCNSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
206010000807 Acute HIV infection Diseases 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
GCTANJIJJROSLH-GVARAGBVSA-N Ala-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C)N GCTANJIJJROSLH-GVARAGBVSA-N 0.000 description 1
ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 description 1
YEBZNKPPOHFZJM-BPNCWPANSA-N Ala-Tyr-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O YEBZNKPPOHFZJM-BPNCWPANSA-N 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
206010012426 Dermal cyst Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
208000037487 Endotoxemia Diseases 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
RWQCWSGOOOEGPB-FXQIFTODSA-N Gln-Ser-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O RWQCWSGOOOEGPB-FXQIFTODSA-N 0.000 description 1
IHDKKJVBLGXLEL-STQMWFEESA-N Gly-Tyr-Met Chemical compound CSCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(O)=O IHDKKJVBLGXLEL-STQMWFEESA-N 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
UDLAWRKOVFDKFL-PEFMBERDSA-N Ile-Asp-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N UDLAWRKOVFDKFL-PEFMBERDSA-N 0.000 description 1
IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
208000009388 Job Syndrome Diseases 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
150000008575 L-amino acids Chemical group 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 1
241000239218 Limulus Species 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101150004219 MCR1 gene Proteins 0.000 description 1
BLIPQDLSCFGUFA-GUBZILKMSA-N Met-Arg-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O BLIPQDLSCFGUFA-GUBZILKMSA-N 0.000 description 1
CWFYZYQMUDWGTI-GUBZILKMSA-N Met-Arg-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O CWFYZYQMUDWGTI-GUBZILKMSA-N 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
OLNLSTNFRUFTLM-BYPYZUCNSA-N N-ethyl-L-asparagine Chemical compound CCN[C@H](C(O)=O)CC(N)=O OLNLSTNFRUFTLM-BYPYZUCNSA-N 0.000 description 1
OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
108010065338 N-ethylglycine Proteins 0.000 description 1
KSPIYJQBLVDRRI-WDSKDSINSA-N N-methyl-L-isoleucine Chemical compound CC[C@H](C)[C@H](NC)C(O)=O KSPIYJQBLVDRRI-WDSKDSINSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
240000001987 Pyrus communis Species 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
101001033266 Rattus norvegicus Interleukin-10 Proteins 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000021388 Sezary disease Diseases 0.000 description 1
244000191761 Sida cordifolia Species 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
206010043784 Thyroiditis subacute Diseases 0.000 description 1
102000001400 Tryptase Human genes 0.000 description 1
108060005989 Tryptase Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
KKHRWGYHBZORMQ-NHCYSSNCSA-N Val-Arg-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKHRWGYHBZORMQ-NHCYSSNCSA-N 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000012876 acute enteritis Diseases 0.000 description 1
230000010398 acute inflammatory response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002001 anti-metastasis Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
230000001042 autoregulative effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000006480 benzoylation reaction Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
150000001576 beta-amino acids Chemical class 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000001273 butane Substances 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000012085 chronic inflammatory response Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000010252 digital analysis Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
IDAGXRIGDWCIET-SDFKWCIISA-L disodium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IDAGXRIGDWCIET-SDFKWCIISA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
108010072542 endotoxin binding proteins Proteins 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
108010010147 glycylglutamine Proteins 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000001165 hydrophobic group Chemical class 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
206010051040 hyper-IgE syndrome Diseases 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000002977 hyperthermial effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
230000007233 immunological mechanism Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001451 polypropylene glycol Chemical class 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000004080 punching Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005488 sandblasting Methods 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
ZNVGYHOBTCWGTO-UHFFFAOYSA-N solutin Natural products Cc1cc(O)cc2OC(C)(O)C(=O)c12 ZNVGYHOBTCWGTO-UHFFFAOYSA-N 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
201000007497 subacute thyroiditis Diseases 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000008181 tonicity modifier Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

KR1019980705491A 1996-01-18 1997-01-16 합성 il-10 동족체 Ceased KR19990077344A (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/DK1996/000029 WO1997026278A1 (en)	1996-01-18	1996-01-18	Synthetic il-10 analogues
DKPCT/DK96/00029		1996-01-18

Publications (1)

Publication Number	Publication Date
KR19990077344A true KR19990077344A (ko)	1999-10-25

Family

ID=8155499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1019980705491A Ceased KR19990077344A (ko)	1996-01-18	1997-01-16	합성 il-10 동족체

Country Status (14)

Country	Link
US (1)	US6936586B1 (2)
EP (1)	EP0879245A1 (2)
JP (1)	JP2000503652A (2)
KR (1)	KR19990077344A (2)
CN (1)	CN1226899A (2)
AP (1)	AP883A (2)
AR (1)	AR006517A1 (2)
AU (2)	AU4385696A (2)
BR (1)	BR9707036A (2)
CA (1)	CA2243275A1 (2)
PL (1)	PL327928A1 (2)
RU (1)	RU2194054C2 (2)
WO (2)	WO1997026278A1 (2)
ZA (1)	ZA9784B (2)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997026278A1 (en) *	1996-01-18	1997-07-24	Steeno Research Group A/S	Synthetic il-10 analogues
WO1998010792A1 (en) *	1996-09-11	1998-03-19	Prendergast Patrick T	Immune direction therapy
AU9449398A (en) *	1997-10-10	1999-05-03	Imperial College Innovations Ltd.	Use of csaidtm compounds for the management of uterine contractions
DE19851675A1 (de) *	1998-11-10	2000-05-11	Bayer Ag	Menschliche Interleukin-10 Mutantenproteine
US6685931B1 (en)	1998-12-22	2004-02-03	Schering Corporation	Treatment of hepatitis C virus infections with interleukin-10
EP1265634A4 (en) *	2000-03-14	2005-12-28	Nat Jewish Med & Res Center	METHOD AND COMPOSITION FOR TREATING RESPIRATORY HYPERSENSIBILITY
US20070160576A1 (en) *	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6797722B2 (en) *	2002-05-03	2004-09-28	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
RU2260598C2 (ru) *	2003-10-29	2005-09-20	Российский кардиологический научно-производственный комплекс Министерства здравоохранения РФ	Пептид, обладающий способностью ингибировать миграцию моноцитарных клеток, стимулированную белком мср-1
GB0500643D0 (en) *	2005-01-13	2005-02-23	Renovo Ltd	Medicaments
PL2118123T3 (pl)	2007-01-31	2016-06-30	Dana Farber Cancer Inst Inc	Stabilizowane peptydy p53 i ich zastosowania
JP5631201B2 (ja)	2007-03-28	2014-11-26	プレジデントアンドフェローズオブハーバードカレッジ	ステッチングされたポリペプチド
AU2014201269B2 (en) *	2008-02-08	2016-09-15	Aileron Therapeutics, Inc.	Therapeutic peptidomimetic macrocycles
CN104474529A (zh)	2008-02-08	2015-04-01	爱勒让治疗公司	治疗性的拟肽大环化合物
EP2768518A4 (en)	2011-10-18	2015-05-27	Aileron Therapeutics Inc	PEPTIDOMIMETIC MACROCYCLES
CA2864120A1 (en)	2012-02-15	2013-08-22	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru)	2012-02-15	2018-01-24	Эйлерон Терапьютикс, Инк.	P53 пептидомиметические макроциклы
WO2014138429A2 (en)	2013-03-06	2014-09-12	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and use thereof in regulating hif1alpha
EP3197478A4 (en)	2014-09-24	2018-05-30	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles and uses thereof
JP2018516844A (ja)	2015-03-20	2018-06-28	エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ペプチド模倣大環状分子およびその使用
EP3347372A4 (en)	2015-09-10	2019-09-04	Aileron Therapeutics, Inc.	PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
EP3551034A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
CA3054156A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2020106757A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
BR102019007044A2 (pt) *	2019-04-05	2021-12-28	Universidade Federal de Uberlândia	Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
IL94878A (en) *	1989-06-28	2003-01-12	Schering Corp	Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
US5624823A (en) *	1991-11-22	1997-04-29	The General Hospital Corporation	DNA encoding procine interleukin-10
CA2131524A1 (en)	1992-03-04	1993-09-16	Maria-Grazia Roncarolo	Use of interleukin-10 to suppress graft-vs.-host disease
RU2051922C1 (ru) *	1992-06-19	1996-01-10	Людмила Яковлевна Соловьева	СПОСОБ ВЫДЕЛЕНИЯ РЕКОМБИНАНТНОГО ИНТЕРЛЕЙКИНА - 1β ИЗ БИОМАССЫ МИКРООРГАНИЗМОВ
CA2085291A1 (en)	1992-07-30	1994-01-31	Martin L. Breitman	Novel receptor tyrosine kinase
US5328989A (en) *	1993-03-05	1994-07-12	Schering-Plough	Purification of human interleukin-10 from a cell culture medium
US5446128A (en)	1993-06-18	1995-08-29	The Board Of Trustees Of The University Of Illinois	Alpha-helix mimetics and methods relating thereto
IL110413A0 (en)	1993-07-26	1994-10-21	Schering Corp	Agonists and antagonists of human interleukin-10
US6159937A (en) *	1994-07-05	2000-12-12	Steeno Research Group A/S	Immunomodulators
US5654276A (en) *	1995-06-07	1997-08-05	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-5 receptor
WO1997026278A1 (en) *	1996-01-18	1997-07-24	Steeno Research Group A/S	Synthetic il-10 analogues

1996
- 1996-01-18 WO PCT/DK1996/000029 patent/WO1997026278A1/en not_active Ceased
- 1996-01-18 AU AU43856/96A patent/AU4385696A/en not_active Abandoned
1997
- 1997-01-06 ZA ZA9700084A patent/ZA9784B/xx unknown
- 1997-01-16 KR KR1019980705491A patent/KR19990077344A/ko not_active Ceased
- 1997-01-16 BR BR9707036-0A patent/BR9707036A/pt not_active Application Discontinuation
- 1997-01-16 CN CN97193092A patent/CN1226899A/zh active Pending
- 1997-01-16 AU AU13011/97A patent/AU718476B2/en not_active Ceased
- 1997-01-16 CA CA002243275A patent/CA2243275A1/en not_active Abandoned
- 1997-01-16 EP EP97900549A patent/EP0879245A1/en not_active Withdrawn
- 1997-01-16 US US09/101,825 patent/US6936586B1/en not_active Expired - Fee Related
- 1997-01-16 JP JP9525609A patent/JP2000503652A/ja not_active Ceased
- 1997-01-16 WO PCT/DK1997/000021 patent/WO1997026279A1/en not_active Ceased
- 1997-01-16 RU RU98115293/04A patent/RU2194054C2/ru not_active IP Right Cessation
- 1997-01-16 PL PL97327928A patent/PL327928A1/xx unknown
- 1997-01-16 AP APAP/P/1998/001295A patent/AP883A/en active
- 1997-01-17 AR ARP970100194A patent/AR006517A1/es unknown

Also Published As

Publication number	Publication date
EP0879245A1 (en)	1998-11-25
ZA9784B (en)	1997-07-17
CA2243275A1 (en)	1997-07-24
JP2000503652A (ja)	2000-03-28
AU718476B2 (en)	2000-04-13
PL327928A1 (en)	1999-01-04
AU4385696A (en)	1997-08-11
AP883A (en)	2000-10-25
WO1997026278A1 (en)	1997-07-24
BR9707036A (pt)	1999-08-31
RU2194054C2 (ru)	2002-12-10
WO1997026279A1 (en)	1997-07-24
AP9801295A0 (en)	1998-09-30
AU1301197A (en)	1997-08-11
AR006517A1 (es)	1999-09-08
US6936586B1 (en)	2005-08-30
CN1226899A (zh)	1999-08-25

Legal Events

Date	Code	Title	Description
1998-07-16	PA0105	International application	Patent event date: 19980716 Patent event code: PA01051R01D Comment text: International Patent Application
1999-10-25	PG1501	Laying open of application
2002-01-16	A201	Request for examination
2002-01-16	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20020116 Comment text: Request for Examination of Application
2004-03-30	E902	Notification of reason for refusal
2004-03-30	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20040330 Patent event code: PE09021S01D
2004-08-27	E601	Decision to refuse application
2004-08-27	PE0601	Decision on rejection of patent	Patent event date: 20040827 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040330 Comment text: Notification of reason for refusal Patent event code: PE06011S01I

Publication	Publication Date	Title
RU2194054C2 (ru)	2002-12-10	Синтетические аналоги il-10
US6168791B1 (en)	2001-01-02	Antibodies that bind immunomodulators
AU2019375096B2 (en)	2024-03-14	Polypeptides for the treatment of stress, immunoreaction and stroke syndromes
RU98115293A (ru)	2000-05-20	Синтетические аналоги il-10
CA2124461A1 (en)	1993-06-10	Human interleukin-8 analogs
WO1998006751A9 (en)	1998-04-30	Mcp-3, rantes and mip-1alpha receptor antagonists
WO1996009062A1 (en)	1996-03-28	Polypeptide agonists and antagonists of human interleukin-8
CA2348308A1 (en)	2000-05-18	Rantes-derived peptides with anti-hiv activity
JP2003507011A (ja)	2003-02-25	Ｉｌ−１６拮抗剤
CA2397267A1 (en)	2001-08-02	Peptide fragments and uses thereof as type-1 interferon antagonist
WO2001011937A2 (en)	2001-02-22	Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
KR100290224B1 (ko)	2001-05-15	Cxc 인터크린 분자의 펩타이드 억제제
EP0519976A1 (en)	1992-12-30	PEPTIDES STIMULATING NEUTROPHILIC POLYNUCLEARS.
WO2002013849A1 (en)	2002-02-21	Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
RU2136307C1 (ru)	1999-09-10	Способ диагностики депрессии кроветворения
MXPA98005648A (en)	2001-09-07	Synthetic il-10 analogues
HK1012416B (en)	2000-12-01	Immunomodulators
JPH04134095A (ja)	1992-05-07	ロドストミン
KR20000016620A (ko)	2000-03-25	T-세포 선택적 인터루킨-4 아고니스트
CA2178927A1 (en)	1995-06-22	Peptide inhibitors of cxc intercrine molecules